Pancreatic Injury

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 6144 Experts worldwide ranked by ideXlab platform

Sohail Z. Husain - One of the best experts on this subject based on the ideXlab platform.

  • drug induced Pancreatic Injury dipi redefining drug induced pancreatitis in adult and pediatric populations
    Current Treatment Options in Gastroenterology, 2020
    Co-Authors: Sohail Z. Husain, Monique T. Barakat, Emory M. Manten, Jodie A. Barkin
    Abstract:

    Drug-induced pancreatitis is the second most common cause of acute pancreatitis (AP) in children and ranks as the third in adults. The aims of this targeted review are to provide a basis for conceptualizing drug-induced Pancreatic Injury (DIPI), to highlight specific drugs that are common or emerging risk factors, and to suggest a framework for future studies of DIPI. We challenge the traditional notion of diagnosing a drug exposure as the etiology of pancreatitis only after other etiologies could not be identified. Instead, we propose rethinking the disease process as a continuum of Pancreatic Injury due to drug exposure that can be concomitant with other risk factors. We favor a shift to use of the term drug-induced Pancreatic Injury (DIPI). There is a need to better characterize DIPI and to probe the mechanisms underlying the various types of DIPI, for the safer use of the DIPI inducing drugs by thwarting the adverse event of pancreatitis.

  • Drug-Induced Pancreatic Injury (DIPI): Redefining Drug-Induced Pancreatitis in Adult and Pediatric Populations
    Current Treatment Options in Gastroenterology, 2020
    Co-Authors: Monique T. Barakat, Sohail Z. Husain, Emory M. Manten, Jodie A. Barkin
    Abstract:

    Purpose of review Drug-induced pancreatitis is the second most common cause of acute pancreatitis (AP) in children and ranks as the third in adults. The aims of this targeted review are to provide a basis for conceptualizing drug-induced Pancreatic Injury (DIPI), to highlight specific drugs that are common or emerging risk factors, and to suggest a framework for future studies of DIPI. Recent findings We challenge the traditional notion of diagnosing a drug exposure as the etiology of pancreatitis only after other etiologies could not be identified. Instead, we propose rethinking the disease process as a continuum of Pancreatic Injury due to drug exposure that can be concomitant with other risk factors. Summary We favor a shift to use of the term drug-induced Pancreatic Injury (DIPI). There is a need to better characterize DIPI and to probe the mechanisms underlying the various types of DIPI, for the safer use of the DIPI inducing drugs by thwarting the adverse event of pancreatitis.

  • Molecular and cellular mechanisms of Pancreatic Injury.
    Current opinion in gastroenterology, 2010
    Co-Authors: Edwin C. Thrower, Fred S. Gorelick, Sohail Z. Husain
    Abstract:

    Purpose of reviewThis review focuses on studies from the past year that highlight molecular and cellular mechanisms of Pancreatic Injury arising from acute and chronic pancreatitis.Recent findingsFactors that induce or ameliorate Injury as well as cellular pathways involved have been examined. Causa

Fiemu E. Nwariaku - One of the best experts on this subject based on the ideXlab platform.

  • is octreotide beneficial following Pancreatic Injury
    American Journal of Surgery, 1995
    Co-Authors: Fiemu E. Nwariaku, Anthony Terracina, William J. Mileski, Joseph P. Minei, James C Carrico
    Abstract:

    Background: Pancreatic Injury is often associated with multiple complications related to uncontrolled Pancreatic exocrine secretion, including Pancreatic fistula, pseudocyst, and intra-abdominal abscesses. Somatostatin analogues such as octreotide have been shown to decrease pancreas-related morbidity following major Pancreatic resection in patients with Pancreatic neoplasms and acute severe pancreatitis. This study was conducted to determine whether or not the administration of octreotide influences the incidence and severity of abdominal complications following Pancreatic Injury. Patients and methods: Patients with intraoperative diagnosis of Pancreatic Injury over a 6-year period were studied retrospectively. Specific complications assessed include abdominal abscesses, pseudocyst, pancreatitis, and Pancreatic fistula. Statistical analysis of qualitative variables was by chi-square analysis, and analysis of quantitative variables by Student's t-test (P <0.05). Results: Injury to the pancreas was identified in 96 patients. Sixteen early deaths (<48 hours) and one late death occurred, for a mortality of 18%, leaving 80 patients as the study population; 21 patients received octreotide and 55 patients did not. Pancreatic fistula occurred in 32 patients (40%). When stratified by Pancreatic Injury severity, there was no significant difference in complication rates, although patients treated with octreotide had a higher rate of fistula formation (48% versus 40%), longer duration of fistula drainage, and longer hospital stay compared with untreated patients. Conclusion: Although adverse patient selection may be a factor in this retrospective survey, the magnitude of observed differences raises concerns regarding the empiric administration of octreotide to such patients pending prospective study.

  • Is octreotide beneficial following Pancreatic Injury
    American journal of surgery, 1995
    Co-Authors: Fiemu E. Nwariaku, Anthony Terracina, William J. Mileski, Joseph P. Minei, C. James Carrico
    Abstract:

    Background: Pancreatic Injury is often associated with multiple complications related to uncontrolled Pancreatic exocrine secretion, including Pancreatic fistula, pseudocyst, and intra-abdominal abscesses. Somatostatin analogues such as octreotide have been shown to decrease pancreas-related morbidity following major Pancreatic resection in patients with Pancreatic neoplasms and acute severe pancreatitis. This study was conducted to determine whether or not the administration of octreotide influences the incidence and severity of abdominal complications following Pancreatic Injury. Patients and methods: Patients with intraoperative diagnosis of Pancreatic Injury over a 6-year period were studied retrospectively. Specific complications assessed include abdominal abscesses, pseudocyst, pancreatitis, and Pancreatic fistula. Statistical analysis of qualitative variables was by chi-square analysis, and analysis of quantitative variables by Student's t-test (P

Monique T. Barakat - One of the best experts on this subject based on the ideXlab platform.

  • Drug-Induced Pancreatic Injury (DIPI): Redefining Drug-Induced Pancreatitis in Adult and Pediatric Populations
    Current Treatment Options in Gastroenterology, 2020
    Co-Authors: Monique T. Barakat, Sohail Z. Husain, Emory M. Manten, Jodie A. Barkin
    Abstract:

    Purpose of review Drug-induced pancreatitis is the second most common cause of acute pancreatitis (AP) in children and ranks as the third in adults. The aims of this targeted review are to provide a basis for conceptualizing drug-induced Pancreatic Injury (DIPI), to highlight specific drugs that are common or emerging risk factors, and to suggest a framework for future studies of DIPI. Recent findings We challenge the traditional notion of diagnosing a drug exposure as the etiology of pancreatitis only after other etiologies could not be identified. Instead, we propose rethinking the disease process as a continuum of Pancreatic Injury due to drug exposure that can be concomitant with other risk factors. Summary We favor a shift to use of the term drug-induced Pancreatic Injury (DIPI). There is a need to better characterize DIPI and to probe the mechanisms underlying the various types of DIPI, for the safer use of the DIPI inducing drugs by thwarting the adverse event of pancreatitis.

  • drug induced Pancreatic Injury dipi redefining drug induced pancreatitis in adult and pediatric populations
    Current Treatment Options in Gastroenterology, 2020
    Co-Authors: Sohail Z. Husain, Monique T. Barakat, Emory M. Manten, Jodie A. Barkin
    Abstract:

    Drug-induced pancreatitis is the second most common cause of acute pancreatitis (AP) in children and ranks as the third in adults. The aims of this targeted review are to provide a basis for conceptualizing drug-induced Pancreatic Injury (DIPI), to highlight specific drugs that are common or emerging risk factors, and to suggest a framework for future studies of DIPI. We challenge the traditional notion of diagnosing a drug exposure as the etiology of pancreatitis only after other etiologies could not be identified. Instead, we propose rethinking the disease process as a continuum of Pancreatic Injury due to drug exposure that can be concomitant with other risk factors. We favor a shift to use of the term drug-induced Pancreatic Injury (DIPI). There is a need to better characterize DIPI and to probe the mechanisms underlying the various types of DIPI, for the safer use of the DIPI inducing drugs by thwarting the adverse event of pancreatitis.

Jodie A. Barkin - One of the best experts on this subject based on the ideXlab platform.

  • Drug-Induced Pancreatic Injury (DIPI): Redefining Drug-Induced Pancreatitis in Adult and Pediatric Populations
    Current Treatment Options in Gastroenterology, 2020
    Co-Authors: Monique T. Barakat, Sohail Z. Husain, Emory M. Manten, Jodie A. Barkin
    Abstract:

    Purpose of review Drug-induced pancreatitis is the second most common cause of acute pancreatitis (AP) in children and ranks as the third in adults. The aims of this targeted review are to provide a basis for conceptualizing drug-induced Pancreatic Injury (DIPI), to highlight specific drugs that are common or emerging risk factors, and to suggest a framework for future studies of DIPI. Recent findings We challenge the traditional notion of diagnosing a drug exposure as the etiology of pancreatitis only after other etiologies could not be identified. Instead, we propose rethinking the disease process as a continuum of Pancreatic Injury due to drug exposure that can be concomitant with other risk factors. Summary We favor a shift to use of the term drug-induced Pancreatic Injury (DIPI). There is a need to better characterize DIPI and to probe the mechanisms underlying the various types of DIPI, for the safer use of the DIPI inducing drugs by thwarting the adverse event of pancreatitis.

  • drug induced Pancreatic Injury dipi redefining drug induced pancreatitis in adult and pediatric populations
    Current Treatment Options in Gastroenterology, 2020
    Co-Authors: Sohail Z. Husain, Monique T. Barakat, Emory M. Manten, Jodie A. Barkin
    Abstract:

    Drug-induced pancreatitis is the second most common cause of acute pancreatitis (AP) in children and ranks as the third in adults. The aims of this targeted review are to provide a basis for conceptualizing drug-induced Pancreatic Injury (DIPI), to highlight specific drugs that are common or emerging risk factors, and to suggest a framework for future studies of DIPI. We challenge the traditional notion of diagnosing a drug exposure as the etiology of pancreatitis only after other etiologies could not be identified. Instead, we propose rethinking the disease process as a continuum of Pancreatic Injury due to drug exposure that can be concomitant with other risk factors. We favor a shift to use of the term drug-induced Pancreatic Injury (DIPI). There is a need to better characterize DIPI and to probe the mechanisms underlying the various types of DIPI, for the safer use of the DIPI inducing drugs by thwarting the adverse event of pancreatitis.

Shangxin Deng - One of the best experts on this subject based on the ideXlab platform.

Pancreatic Injury - 15 days free trial to Access Experts & Abstracts